In the latest in our new series on improving care for people with long-term health conditions, Dods Impact and AbbVie explore how the use of digital images for skin legions can deliver a step change in treatment for inflammatory skin conditions
Inflammatory skin conditions such as psoriasis or eczema can have a profound and debilitating impact on people of all ages. They are also a major issue for NHS capacity. Ask any practicing GP, and they will tell you that skin conditions account for up to a third of all appointments.
Living with an inflammatory skin condition can also have serious consequences for mental as well as physical health. In a recent survey by the APPG on Skin, 93% of respondents said that their skin condition impacted on their self-esteem, 5% reported that they had even contemplated suicide.
Chair of the APPG Sir Edward Leigh, who himself suffers from rosacea, is concerned that the pandemic has had a profound impact on those living with inflammatory skin conditions.
The waiting time for patients with long-term skin conditions to see a secondary care specialist has been growing for years, he tells us. This has only been exacerbated by the pandemic.
Dominic Urmston, from the Psoriasis Association shares Leighs concerns. He has heard from many patients who have had their treatments disrupted.
During the pandemic many people with inflammatory skin conditions saw face-to-face appointments either changed to remote consultations or cancelled altogether, he explains. This has led to an appointment backlog and increased waiting times for specialist care, with many people seeing their symptoms worsen in the meantime.
Urmstons experience has now been backed up by a recent report, commissioned and funded by biopharmaceutical company AbbVie and carried out by health research consultancy Carnell Farrar.
The report highlights the impact of the pandemic on the diagnosis and treatment of conditions like eczema and psoriasis. It reports that during the first year of the pandemic first outpatient attendances for dermatology plummeted by 28%, while elective hospital admissions for psoriasis alone fell by the same number.This is one of the largest falls seen within any patient group. As a result, while we know around 300,000 patients are currently on the routine waiting list, the overall backlog of patients could be much higher one hypothecated model by Carnall Farrar suggests over 900,000 patients were unaccounted for during the first 18 months of the pandemic and are potentially still in need of care.*
Appointment levels are now slowly recovering, Todd Manning, General Manager at AbbVie, but even if they reach pre-pandemic levels that alone will not come close to clearing the backlog created by the pandemic unless new ways can be found to increase capacity within the system to allow more patients to be seen when they need it. All sectors and organisations need to work collaboratively and creatively to find new ways to reach and care for those with inflammatory skin conditions.
There is however a strong foundation for developing new approaches. Dr Julia Schofield, Dermatology Clinical Lead for NHS England, told us that technology is already playing an important role in delivering better care to those with serious skin conditions.
The NHS is transforming dermatologyoutpatientservicestoensure that patientshavebetter access to specialistcare that works for them, she explains. Bymaking better use of technologysuch asdigital images, we are reducing the need for unnecessary face-to-face appointments,and are giving patients the freedom tobook outpatient appointments when they need them to ensure care is responsive to their individual condition.
The use of digital images for the assessment of people, particularly with skin lesions, is already making a difference. Dr Schofield explained that it is helping to reduce the number of people that need to attend hospitals and freeing up capacity for those people, usually with inflammatory skin diseases, that need to be seen face to face in dermatology clinics. As a result there are growing calls for a further acceleration in the rollout of these new approaches and other digitally enabled solutions that support out of hospital care and patient self-management to further reduce capacity pressures.
Bymaking better use of technologysuch asdigital images, we are reducing the need for unnecessary face-to-face appointments,and are giving patients the freedom tobook outpatient appointments when they need them to ensure care is responsive to their individual condition.
Some waiting times are now quoted in years, not months, Sir Edward Leigh tells us. New ways of working will have to be trialled and adopted to improve this intolerable situation.
Todd Manning also believes that the new ways of working that Schofield advocates should be must now be prioritised for adoption.
Covid saw a massive increase in telephone appointments, but for inflammatory skin diseases diagnosis over the telephone is highly challenging, he explains. The use of digital technology is about enabling how the whole system can work more efficiently. Effectivesharing of information, particularly between primary and secondary care providers is key. The Carnall Farrar research shows that better use of digital imagery to support the two week wait cancer referral process could save up to48,000 consultant hours that could be released to increase capacity for eczema and other dermatology cases, reducing anxiety for patients.
Delivering these benefits will require shifts in how Integrated Care Boards commission dermatology services, more support and education for frontline staff across a patients treatment journey to help them understand and deliver new care pathways, and investment in new technologies. This was a recommendation emerging from a recent parliamentary roundtable on the issue chaired by Sir Edward Leigh, alongside the need for more national leadership and accountability to help drive this change.
However, the prize on offer is substantial. The increased use of digital and remote care solutions could lead to speedier diagnoses, better patient outcomes, and more effective use of healthcare resources. Not only will this benefit the millions of people in Englandliving with inflammatory skin conditions, it will also benefit the NHS as a whole - a prize well worth securing.
How Teledermatology is Improving Cancer Care for Patients in Leeds
One of the ways that new technologies can help patients and speed up processes for GPs and consultants is by enabling diagnosis to take place quickly and without the need for an outpatient appointment.
In Leeds, a project has been looking at ways to deliver fastand accurate diagnoses around lesions that might indicate skin cancers. The scheme began when a consultant dermatologist realised that a third of all patients referred to consultants were ultimately discharged without any clinical intervention.
He realised that if new technology could be used to move these patients through the system more quickly that would reduce anxiety and save time and money for health providers.
Until the new system was put into place, each of these patients would have had to attend a face-to-face appointment. Not only did that lead to anxiety and concern, but it also created pressure on the secondary care system.
The solution that has been put in place to achieve this is a specialist magnifying device that is used with a smartphone. This system is now used by every GP practice in Leeds.
At the initial appointment GPs, with patient consent, take three pictures of any concerning skin lesion. These are then sent securely to the consultants at Leeds Teaching Hospital Trust. Within 48 hours those consultants report back, either confirming the lesion is benign or inviting the patient in for a face-to-face appointment.
The new system is faster, more efficient, and more effective than the traditional way of working. It has reduced anxiety for patients, relieved pressure on the 2 week wait pathway, and freed up the capacity of dermatology consultants.
This case study is not connected to AbbVie in any way
This article and the Carnall Farrar report has been commissioned and funded by AbbVie. This article is intended for the general public.Date of Preparation: September 2022 Job No: UK-ABBV-220308
*HES data Mar 19 Nov 21. Backlog calculated from accumulated month on month deficit in observed outpatient appointments compared to average month in year prior to COVID (Mar 19 Feb 20) assuming demographic growth of 3%. 90% of missed activity assumed to flow into backlog. No seasonality and no further disruption assumed
PoliticsHome Newsletters
Get the inside track on what MPs and Peers are talking about. Sign up to The House's morning email for the latest insight and reaction from Parliamentarians, policy-makers and organisations.
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]
- Woman, 29, Slams Bullies Who 'Giggle And Whisper' At Her Unsightly Psoriasis Sores And Scabs, Leaving Her Depressed And 'Struggling To Walk' -... - August 15th, 2022 [August 15th, 2022]